Tim Schaum (left) and Chad Landmon (right) Chad Landmon, who joins in Washington DC, hopes to expand the firm’s Hatch-Waxman practice
Most of these drugs are P-gp inhibitors, but due to high toxicity and pharmacokinetic effects, they have not been used in clinical practice [118]. The current research direction is to develop more efficient and low-toxic chemical drug reversal agents. Dual specificity phosphatase6 (DUSP6) ...
While examining the therapeutic challenges and options for each type of NSCLC metastasis exceeds the scope of the present review, the authors focus on NSCLC-related CNS disease. This type of metastasis affects up to 70% of patients with NSCLC harboring an oncogenic driver mutation during the ...